|
1
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schwitalla S, Fingerle AA, Cammareri P,
Nebelsiek T, Göktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ,
Moreaux G, et al: Intestinal tumorigenesis initiated by
dedifferentiation and acquisition of stem-cell-like properties.
Cell. 152:25–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li G, Ji XD, Gao H, Zhao JS, Xu JF, Sun
ZJ, Deng YZ, Shi S, Feng YX, Zhu YQ, et al: EphB3 suppresses
non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt
signalling complex. Nat Commun. 3:6672012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hessmann E, Zhang JS, Chen NM, Hasselluhn
M, Liou GY, Storz P, Ellenrieder V, Billadeau DD and Koenig A:
NFATc4 regulates Sox9 gene expression in acinar cell plasticity and
pancreatic cancer initiation. Stem Cells Int. 2016:52724982016.
View Article : Google Scholar
|
|
5
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang J, Liu HL, Liu ZH, Tan SW and Wu B:
Identification of cystatin SN as a novel biomarker for pancreatic
cancer. Tumour Biol. 36:3903–3910. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi EH, Kim JT, Kim JH, Kim SY, Song EY,
Kim JW, Kim SY, Yeom YI, Kim IH and Lee HG: Upregulation of the
cysteine protease inhibitor, cystatin SN, contributes to cell
proliferation and cathepsin inhibition in gastric cancer. Clin Chim
Acta. 406:45–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen YF, Ma G, Cao X, Luo RZ, He LR, He
JH, Huang ZL, Zeng MS and Wen ZS: Overexpression of cystatin SN
positively affects survival of patients with surgically resected
esophageal squamous cell carcinoma. BMC Surg. 13:152013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoneda K, Iida H, Endo H, Hosono K,
Akiyama T, Takahashi H, Inamori M, Abe Y, Yoneda M, Fujita K, et
al: Identification of Cystatin SN as a novel tumor marker for
colorectal cancer. Int J Oncol. 35:33–40. 2009.PubMed/NCBI
|
|
10
|
Kumar MS, Pester RE, Chen CY, Lane K, Chin
C, Lu J, Kirsch DG, Golub TR and Jacks T: Dicer1 functions as a
haploinsufficient tumor suppressor. Genes Dev. 23:2700–2704. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lambertz I, Nittner D, Mestdagh P,
Denecker G, Vandesompele J, Dyer MA and Marine JC: Monoallelic but
not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell
Death Differ. 17:633–641. 2010. View Article : Google Scholar
|
|
12
|
Büssing I, Slack FJ and Grosshans H: let-7
microRNAs in development, stem cells and cancer. Trends Mol Med.
14:400–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boyerinas B, Park SM, Shomron N, Hedegaard
MM, Vinther J, Andersen JS, Feig C, Xu J, Burge CB and Peter ME:
Identification of let-7-regulated oncofetal genes. Cancer Res.
68:2587–2591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gurtan AM, Ravi A, Rahl PB, Bosson AD,
JnBaptiste CK, Bhutkar A, Whittaker CA, Young RA and Sharp PA:
Let-7 represses Nr6a1 and a mid-gestation developmental program in
adult fibroblasts. Genes Dev. 27:941–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiao LR, Frampton AE, Jacob J, Pellegrino
L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, et al:
MicroRNAs targeting oncogenes are down-regulated in pancreatic
malignant transformation from benign tumors. PLoS One.
7:e320682012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volinia S, Galasso M, Sana ME, Wise TF,
Palatini J, Huebner K and Croce CM: Breast cancer signatures for
invasiveness and prognosis defined by deep sequencing of microRNA.
Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang
YC, Lu SW, Yu CH, Huang HS, Wang JJ, Tsai CH, et al: Let-7d
functions as novel regulator of epithelial-mesenchymal transition
and chemoresistant property in oral cancer. Oncol Rep.
26:1003–1010. 2011.PubMed/NCBI
|
|
19
|
Ramberg H, Alshbib A, Berge V, Svindland A
and Taskén KA: Regulation of PBX3 expression by androgen and Let-7d
in prostate cancer. Mol Cancer. 10:502011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Childs G, Fazzari M, Kung G, Kawachi N,
Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV,
Prystowsky MB, et al: Low-level expression of microRNAs let-7d and
miR-205 are prognostic markers of head and neck squamous cell
carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tezcan G, Tunca B, Bekar A, Yalcin M,
Sahin S, Budak F, Cecener G, Egeli U, Demir C, Guvenc G, et al:
Ficus carica latex prevents invasion through induction of let-7d
expression in GBM cell lines. Cell Mol Neurobiol. 35:175–187. 2015.
View Article : Google Scholar
|
|
22
|
Nuovo GJ, Garofalo M, Valeri N, Roulstone
V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A,
et al: Reovirus-associated reduction of microRNA-let-7d is related
to the increased apoptotic death of cancer cells in clinical
samples. Mod Pathol. 25:1333–1344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ivo D'Urso P, Fernando D'Urso O, Damiano
Gianfreda C, Mezzolla V, Storelli C and Marsigliante S: miR-15b and
miR-21 as circulating biomarkers for diagnosis of glioma. Curr
Genomics. 16:304–311. 2015. View Article : Google Scholar
|
|
24
|
Yu Y, Nangia-Makker P, Farhana L, G
Rajendra S, Levi E and Majumdar AP: miR-21 and miR-145 cooperation
in regulation of colon cancer stem cells. Mol Cancer. 14:982015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang W, Lin J and Zhang H: miR-126: A
novel regulator in colon cancer. Biomed Rep. 4:131–134. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Madison BB, Jeganathan AN, Mizuno R,
Winslow MM, Castells A, Cuatrecasas M and Rustgi AK: Let-7
represses carcinogenesis and a stem cell phenotype in the intestine
via regulation of Hmga2. PLoS Genet. 11:e10054082015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karin M and Greten FR: NNF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lah TT, Babnik J, Schiffmann E, Turk V and
Skaleric U: Cysteine proteinases and inhibitors in inflammation:
Their role in periodontal disease. J Periodontol. 64(Suppl):
485–491. 1993.PubMed/NCBI
|
|
29
|
Travis J and Potempa J: Bacterial
proteinases as targets for the development of second-generation
antibiotics. Biochim Biophys Acta. 1477:35–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koblinski JE, Ahram M and Sloane BF:
Unraveling the role of proteases in cancer. Clin Chim Acta.
291:113–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barrett AJ: The cystatins: A diverse
superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta.
45:1363–1374. 1986.PubMed/NCBI
|
|
32
|
Lindahl P, Abrahamson M and Björk I:
Interaction of recombinant human cystatin C with the cysteine
proteinases papain and actinidin. Biochem J. 281:49–55. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dickinson DP, Thiesse M, Dempsey LD and
Millar SJ: Genomic cloning, physical mapping, and expression of
human type 2 cystatin genes. Crit Rev Oral Biol Med. 4:573–580.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim JT, Lee SJ, Kang MA, Park JE, Kim BY,
Yoon DY, Yang Y, Lee CH, Yeom YI, Choe YK, et al: Cystatin SN
neutralizes the inhibitory effect of cystatin C on cathepsin B
activity. Cell Death Dis. 4:e9742013. View Article : Google Scholar : PubMed/NCBI
|
